FindTrial
Sign In

assessing the patient satisfaction with vein viewer vs. Conventional methods among patients undergoing intravenous cannulation

A Randomized Controlled trial to assess the success rate and patient satisfaction with vein viewer vs. Conventional methods among patients undergoing intravenous cannulation, admitted in selected wards at AIIMS, Rishikesh.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021148
Enrollment
100
Registered
2019-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I131- Hypertensive heart and chronic kidney disease without heart failure

Interventions

Intervention1: Group -1: Group-I represented the patients where one arm will be cannulated firstly by Vein Viewer method and then for next cannulation, the other arm will be cannualted by conventional

Sponsors

AIIMS rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Willing to participate. Able to understand and response in Hindi and English. Patients admitted in selected wards. Literate patients

Exclusion criteria

Exclusion criteria: Chronic ill patients. Mentally ill patients. Burn patients.

Design outcomes

Primary

MeasureTime frame
to assess the success rate and patient satisfaction with vein viewer vs.Conventional methods among patients undergoing intravenous cannulationTimepoint: 1 month—

Secondary

MeasureTime frame
To assess and compare the pain and satisfaction in cannulation done with vein veiwer vs conventional techniques.Timepoint: 1 month;To assess and compare the success rate of cannulation done with vein viewer vsconventional technique.Timepoint: 1 month—

Countries

India

Contacts

Public ContactRuchika Rani

AIIMS RISHIKESH

ruchikaheera@gmail.com9814143556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026